Introduction Osteoporosis is a well-recognised complication of intestinal malabsorption related to Coeliac Disease. It is diagnosed by dual energy x-ray absorptiometry (DXA). While referral for DXA scanning in other conditions is widely based on 10-year fracture risk calculated by the FRAX tool designed by the WHO, the 2007 BSG guidelines advise screening patients with a higher risk of osteoporosis with a DXA scan, irrespective of 10-year fracture risk as calculated by FRAX.
Methods Aim: We aimed to establish whether the FRAX and linked NOGG tool was a good screener to determine the need for DXA scan in patients with coeliac disease who are at risk of osteoporosis.
Methods: We used the Hospital Nuclear Medicine database to retrieve the records of 50 patients with a diagnosis of coeliac disease who had been investigated with a DXA scan to assess osteoporosis. Using their medical records, we then calculated their FRAX score for risk of major osteoporotic fracture and hip fracture, and the corresponding NOGG guidance. A 10-year fracture risk of 10% or the linked NOGG guidance was considered to be significant to have a DXA scan.
Results Of the 50 patients with Coeliac disease who had DXA scans, 10 had osteoporosis and 40 had either a normal result or osteopaenia. Of these 10 cases, 9 would have also been referred on the basis of a calculated FRAX score and only one case would have been falsely reassured. Of the 40 cases with either a normal DXA scan or osteopaenia, 31 would have been referred for DXA on the basis of the FRAX score, resulting in an unnecessary test. We concluded that a positive FRAX score does not accurately predict osteoporosis in Coeliac disease. The positive predictive value of the FRAX tool to detect osteoporosis in Coeliac disease is low at 22.5%; however the negative predictive value is high, 90%.
Conclusion The use of FRAX to identify patients with Coeliac disease at risk of osteoporosis has a high negative predictive value. It therefore has merit as a screening tool but has little value as a diagnostic test. Although the sample size was too small to show statistical significance, we suggest that FRAX tool could potentially be adopted as a screener in the context of celiac disease to prevent unnecessary DXA scanning. A osteoporosis risk of <10% or a NOGG guidance of reassurance is likely to be associated with a normal DXA scan. Further large studies are needed to validate this hypothesis and also to determine cost benefit of a FRAX driven strategy for osteoporosis in Coeliac Disease.
Disclosure of Interest J. Weightman: None Declared, M. Bridges: None Declared, A. Dhar Consultant for: Honoraria for advisory roles ot the Pharmaceutical Industry, Speaker bureau with: Warner Chilcott UK, Falk Pharma UK, Almirall, Ferring Pharma UK, Astellas UK.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.